Overview Sym004 Versus TAS-102 in Patients With mCRC Status: Withdrawn Trial end date: 2025-12-01 Target enrollment: Participant gender: Summary This is a Phase 3, randomized, open-label, 2-arm trial designed to evaluate overall survival (OS) following treatment with Sym004, an investigational medicinal product (IMP), versus TAS-102 (trifluridine/tipiracil), a comparator (control) agent. Phase: Phase 3 Details Lead Sponsor: Symphogen A/STreatments: Trifluridine